THE ABRAXANE PIVOTAL PHASE III TRIAL INCLUDED OVER 1000
PATIENTS WITH ADVANCED SQUAMOUS AND NONSQUAMOUS NSCLC

ABRAXANE® + carboplatin vs paclitaxel + carboplatin with weekly dosing over 21 day cycle | Primary endpoint: Overall response rate | phase III trial design for advanced non-small cell lung cancer (NSCLC) - chart ABRAXANE® + carboplatin vs paclitaxel + carboplatin with weekly dosing over 21 day cycle | Primary endpoint: Overall response rate | phase III trial design for advanced non-small cell lung cancer (NSCLC) - chart

Treatment administered until disease progression or development of unacceptable toxicity

*The efficacy and safety of ABRAXANE + carboplatin based on PD-L1 status have not been established.


Studied in a broad range of chemonaïve patients with advanced NSCLC
Studied in a broad range of chemonaïve patients with advanced NSCLC
Stratified by histologies and age 11,12

ABRAXANE + carboplatin arm (n=521)

ABRAXANE® arm patients stratified by histologies (44% squamous cell carcinoma, 49% adenocarcinoma, 2% large cell carcinoma, 6% other) & age (31% ≥65 years of age, 69% <65 years of age)  from advanced non-small cell lung cancer (NSCLC) phase III clinical trial  - pie chart ABRAXANE® arm patients stratified by histologies (44% squamous cell carcinoma, 49% adenocarcinoma, 2% large cell carcinoma, 6% other) & age (31% ≥65 years of age, 69% <65 years of age)  from advanced non-small cell lung cancer (NSCLC) phase III clinical trial  - pie chart


Three-quarters of the patients had a history of smoking 11
Three-quarters of the patients
had a history of smoking 11

ABRAXANE + carboplatin arm (n=519) a

Advanced non-small cell lung cancer (NSCLC) patients smoking history in phase III trial: smoking history (74%), never smoked (26%) - chart Advanced non-small cell lung cancer (NSCLC) patients smoking history in phase III trial: smoking history (74%), never smoked (26%) - chart

  • aThe smoking status was unknown for 2 patients in the ABRAXANE + carboplatin arm.
YOU ARE NOW LEAVING www.abraxanepro.com
Additional Information for Readers Provided by Celgene Corporation

The clinical trial described in this article served as the
basis for the approval for ABRXANE for Injectable Suspension.
The analyses contained in the article may differ from those in the package insert for ABRAXANE.

Please see Important Safety Information and Prescribing Information, including Boxed WARNING.

Click “OK” to proceed or “CANCEL” to return to
www.abraxanepro.com

OK
CANCEL